Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0486 in Mature B-Cell Malignancies (Phase I/II Master Protocol)
2024-515034-33-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Jan 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 2, open-label trial of surovatamig in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL) and 1 more (5 arms), sponsored by AstraZeneca. Primary endpoints: Incidence, nature and severity of AEs/SAEs, Incidence of dose-limiting toxicities (DLTs) and 2 more. Planned start Jan 2025; status: authorised.
02
Drugs
surovatamig
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)mature B-cell lymphoma
Beyond the preview
Go deeper on 2024-515034-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515034-33-00.